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onset endometrioid endometrial cancer with somatic mutation of the CTNNB1 gene; 
CTNNB1-W, tissue samples of early-onset endometrioid endometrial cancer without 
somatic mutation of the CTNNB1 gene; EE, early-onset endometrioid endometrial cancer 
tissue; FGFR2-M, tissue samples of late-onset endometrioid endometrial cancer with 
somatic mutation of the FGFR2 gene; FGFR2-W, tissue samples of late-onset 
endometrioid endometrial cancer without somatic mutation of the FGFR2 gene; GO, gene 
ontology; MPA, medroxyprogesterone acetate; LE, late-onset endometrioid endometrial 
cancer tissue; PCA, principal component analysis; ROC, receiver operating 
characteristic; TSS, transcription start site.
 
Topic: DNA methylation, Infinium array, endometrioid endometrial cancer, early-onset, 
fertility preservation.
Issue Section: ORIGINAL MANUSCRIPT
248 words of abstract, 4,363 words of text, one table, 5 figures and 48 references.
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Abstract
The present study was performed to clarify the significance of DNA methylation 
alterations during endometrial carcinogenesis. Genome-wide DNA methylation analysis 
and targeted sequencing of tumor-related genes were performed using the Infinium 
MethylationEPIC BeadChip and the Ion AmpliSeq Cancer HotSpot Panel v2, 
respectively, for 31 samples of normal control endometrial tissue from patients without 
endometrial cancer and 81 samples of endometrial cancer tissue. Principal component 
analysis revealed that tumor samples had a DNA methylation profile distinct from that of 
control samples. Gene ontology enrichment analysis revealed significant differences of 
DNA methylation at 1,034 CpG sites between early-onset endometrioid endometrial 
cancer (EE) (patients aged <40 years) and late-onset cancer (LE), which were 
accumulated among “transcriptional factors”. Mutations of the CTNNB1 gene or DNA 
methylation alterations of genes participating in Wnt signaling were frequent in EEs, 
whereas genetic and epigenetic alterations of FGF signaling genes were observed in LEs. 
Unsupervised hierarchical clustering grouped EE samples into Clusters EA (n=22) and 
EB (n=12). Clinicopathologically less aggressive tumors tended to be accumulated in 
Cluster EB, and DNA methylation levels of 18 genes including HOXA9, HOXD10 and 
SOX11 were associated with differences in such aggressiveness between the two clusters. 
We identified eleven marker CpG sites that discriminated EB samples from EA samples 
with 100% sensitivity and specificity. These data indicate that genetically and 
epigenetically different pathways may participate in the development of EEs and LEs, 
and that DNA methylation profiling may help predict tumors that are less aggressive and 
amenable to fertility preservation treatment.
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Summary
Genome-wide analysis using 112 samples of endometrial tissue has revealed that 
genetically and epigenetically different pathways may participate in early- and late-onset 
endometrial carcinogenesis. DNA methylation profiling may predict tumors that are less 
aggressive and amenable to fertility preservation treatment.
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Introduction
Endometrial cancer is one of the most common gynecological malignancies in the 
developed countries, with about 320,000 new cases diagnosed annually worldwide (1). 
Although it is typically a disease of post-menopausal women, approximately 2-14% of 
cases occur in women aged 40 years or less (2-4), and in fact recently endometrial cancer 
in younger patients has shown a marked increase (4). The standard treatment for 
endometrial　 cancer　 is　hysterectomy　 and　bilateral　 salpingo-oophorectomy 
with or without lymph node dissection, but for younger patients fertility-sparing treatment 
that avoids surgical menopause needs to be considered. Currently, conservative treatment 
with hormones such as medroxyprogesterone acetate (MPA) is used for early-stage early-
onset endometrial cancer without myometrial invasion or extrauterine spread (5). 
However, we have reported previously that the recurrence rate after MPA therapy is 
63.2%, and the resulting pregnancy rate lower than would be desired (6). In order to 
improve the outcome of medical treatment for patients with endometrial cancer, there is 
a need to clarify the molecular basis of endometrial carcinogenesis, especially in young 
patients.
It is well known that not only genomic but also epigenomic alterations participate 
in carcinogenesis in various human organs (7,8). DNA methylation alterations are one of 
the most important epigenomic changes resulting in chromosomal instability and aberrant 
expression of tumor-related genes (9-11). We and other groups have shown that DNA 
methylation alterations are frequently associated with tumor aggressiveness and poorer 
patient outcome, and can be employed clinically as prognostic markers in cancers of 
various organs (12-17). Recently single-CpG resolution genome-wide DNA methylation 
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screening using the Infinium assay has been introduced for analysis of human tissue 
specimens. However, none of previous studies of endometrial cancer based on the 
Infinium assay (18-22), including the study by The Cancer Genome Atlas (TCGA) (23), 
focused on early-onset endometrial cancer. 
In the present study, to further clarify the significance of DNA methylation 
alterations during endometrial carcinogenesis and their correlation with genetic 
abnormalities, we performed genome-wide DNA methylation (methylome) analysis 
using the high-density EPIC BeadChip on 31 samples of normal control endometrial 
tissue from patients without endometrial cancer and 81 samples of endometrial cancer 
tissue including 35 samples of early-onset endometrial cancer.
Materials and methods
Patients and tissue samples
The 81 samples of cancerous tissue were obtained from 81 patients with primary 
endometrial cancer who underwent hysterectomy at Keio University Hospital between 
October 2005 and August 2016. Thirty-five of the patients were aged 40 years or less 
(early-onset endometrial cancer) and 46 were older than 40 years (late-onset endometrial 
cancer). None of these patients had received any preoperative treatment. Supplementary 
Table 1A, available at Carcinogenesis Online, gives details of the ages and 
clinicopathological backgrounds of these patients. Histological diagnosis and grading 
were based on the 2003 World Health Organization classification (24) and the Tumor-
Node-Metastasis classification (25). The clinical stage of the disease was based on the 
2008 revised International Federation of Gynecology and Obstetrics classification (26). 
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Recurrence was diagnosed by clinicians on the basis of physical examination and imaging 
modalities such as computed tomography and positron emission tomography.
For comparison, 31 samples of normal control endometrial tissue were obtained from 
materials that had been surgically resected from patients without endometrial cancer 
(Supplementary Table 1B, available at Carcinogenesis Online): 17, 6, 6, and 2 patients 
with uterine leiomyoma, ovarian cancer, cervical cancer and lobular endocervical 
glandular hyperplasia, respectively.
Tissue specimens were frozen immediately after surgery and preserved in the Keio 
Women’s Health Biobank in accordance with the “Japanese Society of Pathology 
Guidelines for the handling of pathological tissue samples for genomic research” (27). 
This study was approved by the Ethics Committee of Keio University Hospital and was 
performed in accordance with the Declaration of Helsinki. All patients included in this 
study provided written informed consent for use of their materials.
Infinium analysis 
High-molecular-weight DNA was extracted from fresh frozen tissue samples using 
phenol-chloroform, followed by dialysis. DNA methylation status at 866,895 CpG loci 
was examined at single-CpG resolution using the Infinium MethylationEPIC BeadChip 
(Illumina, San Diego, CA) (28). Five-hundred-nanogram aliquots of DNA were subjected 
to bisulfite conversion using an EZ DNA Methylation-Gold Kit (Zymo Research, Irvine, 
CA). After hybridization, the specifically hybridized DNA was fluorescence-labeled by 
a single-base extension reaction and detected using an iScan reader (Illumina) in 
accordance with the manufacturer’s protocol. The data were then assembled using 
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GenomeStudio methylation software (Illumina). At each CpG site, the ratio of the 
fluorescence signal was measured using a methylated probe relative to the sum of the 
methylated and unmethylated probes, i.e. the so-called -value, which ranges from 0.00 
to 1.00 reflecting the methylation level of an individual CpG site. 
In the present assay, the call proportions (P <0.01 for detection of signals above 
the background) for 801 probes on autosomes in all of the 112 tissue samples were less 
than 90%. Since such a low proportion may have been attributable to polymorphism at 
the probe CpG sites, these probes were excluded from the present assay. In addition, to 
avoid any gender-specific methylation bias, all 19,681 probes on chromosomes X and Y 
were excluded, leaving a final total of 846,413 autosomal CpG sites. Correlations 
between levels of DNA methylation and mRNA expression were examined using the 
dataset for endometrial cancer deposited in the TCGA database (https://tcga-
data.nci.nih.gov/docs/publications/ucec_2013/) (23).
 
Targeted sequencing analysis of 50 tumor-related genes
Targeted sequencing of 50 tumor-related genes was performed in 81 endometrial 
cancer tissue samples.  Library preparation was performed using an Ion AmpliSeq 
Library Kit 2.0-96LV and Ion AmpliSeq Cancer Hotspot Panel v2 in accordance with the 
manufacturer’s protocol (Thermo Fisher Scientific, Waltham, MA). The panel is designed 
to amplify 207 amplicons covering 2,849 mutations of 50 oncogenes and tumor 
suppressor genes deposited in the Catalogue of Somatic Mutations in Cancer (COSMIC) 
database (https://cancer.sanger.ac.uk) (Supplementary Table 2, available at 
Carcinogenesis Online). After library preparation, each amplicon library was quantified 
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using an Ion Library Quantitation Kit on the 7500 Fast Real-Time PCR System (Thermo 
Fisher Scientific) employing the relative standard curve method. Next, emulsion PCR and 
Ion SphereTM particle enrichment were carried out using the Ion OneTouchTM 2 system 
and Ion OneTouchTM ES system (Thermo Fisher Scientific). Purified Ion Sphere TM 
particles were loaded on an Ion 316 or 318 Chip and sequenced using the Ion PGMTM 
sequencer (Thermo Fisher Scientific). Data were analyzed using Torrent Suite Software 
v5.2.2 and Ion Reporter Software v5.2-5.4 (Thermo Fisher Scientific). Detected variants 
with quality scores of <20 and allele frequencies of <2.0% were eliminated in accordance 
with the manufacturer’s instructions. We filtered out single nucleotide polymorphisms 
using the databases of the 1000 Genomes project (http://www.internationalgenome.org/) 
and 5000 exomes project (http://evs.gs.washington.edu/EVS/). Effects of amino acid 
substitutions on protein function due to single-nucleotide non-synonymous mutations 
were estimated using the Sorting Intolerant from Tolerant (SIFT) protocol (29) 
(http://sift.jcvi.org). Copy number analyses were performed using the baseline of 5 
normal human kidney tissue samples without kidney cancer, and confidence levels of <10 
were eliminated in accordance with the manufacturer’s instructions. The incidence of 
genetic aberrations in the present cohort was compared against the dataset for endometrial 
cancer deposited in the TCGA database (https://tcga-
data.nci.nih.gov/docs/publications/ucec_2013/) (23).  
Gene ontology (GO) enrichment analysis and pathway analysis
In order to reveal the function of proteins encoded by genes showing DNA methylation 
alterations and gene mutations, and to reveal the biological processes in which such 
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proteins participate, GO enrichment analysis and pathway analysis were conducted using 
the GeneGO MetacoreTM software package (version 6.7) (Thomson Reuters, New York, 
NY). 
Statistics
Infinium probes showing significant differences in DNA methylation levels between 
sample groups were defined by Welch’s t test and adjusted by Bonferroni correction. The 
DNA methylation profiles of the 112 tissue samples were analyzed using principal 
component analysis (PCA). Differences in the incidences of genetic aberrations between 
sample groups were examined using Fisher’s exact test. Unsupervised hierarchical 
clustering based on DNA methylation levels (Euclidean distance, Ward method and 
Canberra distance, Complete linkage method) was performed. The associations between 
clinicopathological variables and DNA methylation alterations were evaluated using 
Fisher’s exact test, Mann-Whitney U test or Welch’s t test. The receiver operating 
characteristic (ROC) curve was generated, and the Youden index (30) for each probe was 
used as a cutoff value for examining distinctions between the sample groups. Programing 
language R and IBM SPSS statistics 20.0 were used to analyze the data.
Results
DNA methylation alterations during endometrial carcinogenesis
First, to obtain a general overview of endometrial cancers, we identified 58,958 probes 
that were aberrantly methylated in 81 endometrial cancer tissue samples in comparison 
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with the 31 normal control endometrial tissue samples (Welch’s t test, adjusted 
Bonferroni correction [=1.18×10-8] and endometrial cancer tissue–normal control endometrial tissue 
value of more than 0.25 or less than -0.25), indicating that DNA methylation alterations 
had occurred during endometrial carcinogenesis. PCA using the DNA methylation levels 
of these 58,958 probes revealed that endometrial cancer tissue samples had a DNA 
methylation profile that differed distinctly from that of normal control endometrial tissue 
samples (Figure 1A). The leading 10 genes, i.e. TRIM15, HIST2H3PS2, NBPF19, L1TD1, 
HIST2H2BA, NKAPL, DLX2-AS1, GRM1, ADAM12 and CFAP46, showing significant 
differences in DNA methylation levels between endometrial cancer tissue and normal 
control endometrial tissue are labeled in the Manhattan plot (Figure 1B). To our 
knowledge, no previous English-language papers have yet reported correlations between 
these 10 genes and endometrial cancers: the present study may have revealed novel genes 
potentially associated with endometrial carcinogenesis, although the expression levels 
and functions of these genes will need to be further examined in connection with 
endometrial cancers.
Somatic mutations and copy number alterations (CNAs) in endometrial cancer
Five hundred and thirty-five somatic mutations were detected in 81 endometrial cancer 
tissue samples (6.6±2.9 mutations per sample): 230 synonymous and 305 non-
synonymous. The non-synonymous mutations consisted of 242 missense mutations 
(79%), 44 nonsense mutations (14%), 14 frame shift deletions (5%), 4 frame shift 
insertions (1%), and one frameshift block substitution (0.3%). Genes showing the highest 
incidences of somatic mutations included PTEN in 47 patients (58%), PIK3CA in 44 
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patients (54%), CTNNB1 in 25 patients (31%), and TP53 in 15 patients (19%). When 
compared with data for endometrial cancer deposited in the TCGA database (https://tcga-
data.nci.nih.gov/docs/publications/ucec_2013/) (23), the incidences of somatic mutations 
of the MLH1 (P=1.08×10-3), SMARCB1 (P=3.01×10-3), AKT1 (P=0.017) and STK11 
(P=3.47×10-3) genes were higher, and the incidences of those of the FBXW7 (P=0.037), 
ATM (P=0.049), EZH2 (P=0.043), GNAS (P=0.043) and JAK2 (P=0.044) genes were 
lower in our cohort, whereas significant differences were not found in the remaining 41 
genes (Figure 2A). The incidences of CNAs of all the 50 genes examined were lower than 
10%, and this low incidence was again in accordance with the data deposited in the TCGA 
database (https://tcga-data.nci.nih.gov/docs/publications/ucec_2013/) (23) (Figure 2B).
Differences in DNA methylation profile between early- and late-onset endometrioid 
endometrial cancers
In order to avoid the bias caused by differences in histological subtypes, we then focused 
on the major subtype, i.e. endometrioid endometrial cancer. We again identified 63,033 
probes that showed significant differences in DNA methylation levels between the 31 
normal control endometrial tissue samples and 74 endometrioid endometrial cancer tissue 
samples (Welch’s t test, adjusted Bonferroni correction [=1.18×10-8] and endometrioid 
endometrial cancer tissue-normal control endometrial tissue value of more than 0.25 or less than -0.25). 
Next, we focused on differences between early-onset (patients aged <40 years) 
and late-onset (>40 years) endometrioid endometrial cancers. Clinicopathological 
parameters of early- and late-onset cases are summarized in Supplementary Table 3, 
available at Carcinogenesis Online. Among the 63,033 probes, 1,034 showed significant 
Page 12 of 37Carcinogenesis
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Makabe et al. 13
differences in DNA methylation levels between the 34 samples of early-onset 
endometrioid endometrial cancer tissue (EE) and 40 samples of late-onset endometrioid 
endometrial cancer tissue (LE) (Welch’s t test P <0.01; LE-EE value >0.25 or less than 
<-0.25) (Supplementary Table 4, available at Carcinogenesis Online). Since several 
patients (n=11) aged <50 years were included in the LE group, a relatively small number 
of CpG sites showed significant differences in DNA methylation levels between EE and 
LE samples. All 1,034 probes again showed significant differences in DNA methylation 
levels between LE samples and normal control endometrial tissue samples (Welch’s t test 
P <0.01; LE-normal control endometrial tissue value >0.25 or <-0.25), whereas only 102 of 1,034 
probes showed significant differences in DNA methylation levels between EE samples 
and normal control endometrial tissue samples (Welch’s t test P <0.01; EE-normal control 
endometrial tissue value >0.25 or <-0.25). Among these 102 probes, the DNA methylation 
levels of 101 probes were higher in EE samples than in normal control endometrial tissue 
samples and even higher in LE samples.
Three hundred and seventy-one genes, for which the 1,034 probes showing 
significant differences of DNA methylation levels between EE samples and LE samples 
were designed, were evaluated for protein function by enrichment analysis using the 
MetaCore software and compared with the protein function distribution of genes within 
the GeneGo database. These genes were clearly overrepresented by “transcriptional 
factors” (P=1.67×10-32), being 6.004 times more abundant than expected. Indeed 66 of 
371 genes were categorized as transcription factors by MetaCore software (shown by 
asterisks in Supplementary Table 4, available at Carcinogenesis Online). The top 20 
statistically significant GO molecular functions in which the 371 genes participated are 
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listed in Table 1: Fifteen out of the top 20 functions were related to DNA binding or 
transcriptional regulation, and are shown by asterisks, and transcription factors included 
in the top 20 GO molecular functions are underlined in Table 1. All 189 statistically 
significant GO molecular functions (P<0.05) are listed in Supplementary Table 5, 
available at Carcinogenesis Online.
Differences in genetic aberrations between early- and late-onset endometrioid 
endometrial cancers
Two hundred and one somatic mutations (90 synonymous and 111 non-synonymous) 
were detected in 34 samples of EE (5.9±2.2 mutations per sample), whereas 300 
mutations (119 synonymous and 181 non-synonymous) were detected in 40 samples of 
LE (7.5±3.3 mutations per sample). The incidence of somatic mutation of the CTNNB1 
gene was significantly higher in EE samples than in LE samples (P=4.26×10-4), and the 
incidence of that of the FGFR2 gene was significantly higher in LE samples than in EE 
samples (P=8.77×10-3), whereas significant differences were not found in the remaining 
48 genes (Figure 3A). Average SIFT scores for the CTNNB1 and FGFR2 genes were both 
0 in EE samples and LE samples, respectively, indicating that these somatic mutations 
impair protein function (a SIFT score of <0.05 means “damaging” (29)).
Correlation between DNA methylation alterations and genetic aberrations in early- and 
late-onset endometrioid endometrial cancers
In order to clarify the correlation between DNA methylation alterations and genetic 
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aberrations in EE samples, we identified 2,908 probes that showed significant differences 
in DNA methylation levels between 19 EE samples with somatic mutation of the CTNNB1 
gene (CTNNB1-M) and 15 EE samples without it (CTNNB1-W) (Welch’s t test P <0.01; 
CTNNB1-M-CTNNB1-W value >0.15 or <-0.15) (Supplementary Table 6, available at 
Carcinogenesis Online). MetaCore pathway analysis revealed that 1,419 genes for which 
these 2,908 probes were designed were significantly accumulated in the Wnt signaling 
pathway (P=3.45×10-8) (Figure 3B). We identified 1,133 probes that showed significant 
differences in DNA methylation levels between 10 LE samples with somatic mutation of 
the FGFR2 gene (FGFR2-M) and 30 LE samples without it (FGFR2-W) (Welch’s t test 
P <0.01;  FGFR2-M-FGFR2-W value >0.15 or <-0.15) (Supplementary Table 7, available at 
Carcinogenesis Online). Three of the 567 genes for which these 1,133 probes were 
designed were included in the FGF signaling pathway according to the MetaCore 
software (Supplementary Figure 1, available at Carcinogenesis Online). 
Epigenetic clustering of endometrioid endometrial cancer based on DNA methylation 
profile
Unsupervised hierarchical clustering using 63,033 probes showing significant differences 
in DNA methylation levels between the 31 normal control endometrial tissue samples and 
74 endometrioid endometrial cancer tissue samples subclustered the cancer patients into 
Cluster A (n=58) and Cluster B (n=16) (Figure 4A). The clinicopathological parameters 
of the patients in these clusters are summarized in Supplementary Table 8A, available at 
Carcinogenesis Online. Patients in Cluster A were significantly older, showed 
significantly frequent lymphovascular invasion and tended to be more frequently 
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diagnosed as histological grade 3 than those in Cluster B. 
Kaplan-Meier survival curves of patients belonging to Clusters A and B were 
plotted for a period ranging from 263 to 4,034 days (median, 1,605 days). Although the 
cancer-free and overall patient survival rates tended to be lower in Cluster A than in 
Cluster B, such differences did not reach statistically significant levels (P=0.24 and 
P=0.53, respectively, log-rank test), probably due to the small number of deaths or 
recurrent cases (Supplementary Figure 2, available at Carcinogenesis Online). Moreover, 
all recurrence-positive (n=4) and disease-specific death-positive (n=1) cases were 
included in Cluster A (Supplementary Table 8A, available at Carcinogenesis Online).
Unsupervised hierarchical clustering using 40,589 probes showing significant 
differences in DNA methylation levels between the 31 normal control endometrial tissue 
samples and 34 EE samples (Welch’s t test, adjusted Bonferroni correction [α=1.18×10-
8]; ΔβEE-normal control endometrial tissue value >0.25 or <-0.25) subclustered 34 early-onset 
endometrioid endometrial cancer patients into Cluster EA (n=22) and Cluster EB (n=12) 
(Figure 4B). The clinicopathological parameters of the patients in these clusters are 
summarized in Supplementary Table 8B, available at Carcinogenesis Online. Patients in 
Cluster EA tended to show more frequent lymphovascular invasion and to be more 
frequently diagnosed as histological grade 3 than those in Cluster EB. 
The cancer-free survival rate of patients belonging to Cluster EA tended to be lower 
than that of patients in Cluster EB, although the difference did not reach a statistically 
significant level (P=0.37, log-rank test), probably due to the small number of recurrent 
cases (Supplementary Figure 2, available at Carcinogenesis Online). Only one recurrence 
case was included in Cluster EA (Supplementary Table 8B, available at Carcinogenesis 
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Online). Since the overall survival rate was 100% in both Clusters EA and EB, the log-
rank test was not performed. Moreover, all patients belonging to Cluster EA were 
included in Cluster A and all patients belonging to Cluster EB were included in Cluster 
B without exception (Figure 4C). 
As seen in Figure 4B, Probe Clusters I and III showed obvious differences in DNA 
methylation levels between Clusters EA and EB. Furthermore, the ratio of probes located 
in CpG islands, CpG island shores and CpG island shelves that were important for 
transcription regulation to all probes belonging to Probe Cluster I was significantly higher 
than that of probes in Probe Cluster III. We then focused on Probe Cluster I, in which 927 
of the 6,415 probes were designed from the transcription start site (TSS) to 1500 bp 
upstream of the TSS of the 470 genes. One hundred and one (Supplementary Table 9A, 
available at Carcinogenesis Online) of the 470 genes showed a significant (P<0.05) 
inverse correlation (r < -0.2) between DNA methylation levels and the mRNA expression 
levels in the TCGA database (https://tcga-
data.nci.nih.gov/docs/publications/ucec_2013/) (23). The 101 genes were also evaluated 
for protein function by enrichment analysis using the MetaCore software and compared 
with the protein function distribution of genes within the GeneGo database 
(Supplementary Table 9B, available at Carcinogenesis Online). Fifty-nine statistically 
significant GO molecular functions in which the 101 genes participated are listed in 
Supplementary Table 9C (available at Carcinogenesis Online). DNA methylation levels 
of 18 of the 101 genes, including HOXA9, HOXD10 and SOX11, were significantly 
correlated with a higher incidence of lymphovascular invasion of early-onset 
endometrioid endometrial cancer (Supplementary Table 10, available at Carcinogenesis 
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Online). 
Identification of marker CpG sites for distinguishing Cluster EB from Cluster EA
In order to identify diagnostic markers capable of distinguishing the less aggressive 
Cluster EB from Cluster EA, ROC analysis was performed using the top 100 probes 
showing the largest differences in DNA methylation levels between EA and EB samples, 
and the corresponding AUC values were calculated. Among the 100 probes, 11 showed 
AUC values of 1 (Supplementary Table 11, available at Carcinogenesis Online). The 
Youden index was used as a cutoff value for each of the 11 probes. As shown by the 
scattergrams in Figure 5, the use of such cutoff values was able to discriminate EB 
samples from EA samples with 100% sensitivity and specificity. The DNA methylation 
levels of these 11 candidate marker CpG sites were successfully verified using another 
quantification method, MassARRAY: significant correlations between DNA methylation 
levels demonstrated by Infinium assay and those by MassARRAY were confirmed 
(Supplementary Figure 3, available at Carcinogenesis Online).
Discussion
We focused on the differences between early- and late-onset cancers of the major 
histological subtype, i.e. endometrioid endometrial cancer. The incidence of somatic 
mutations of the CTNNB1 gene was significantly higher in EE samples than in LE 
samples, whereas somatic mutations of the FGFR2 gene were more frequent in LE 
samples than in EE samples. Moreover, DNA methylation alterations and genetic 
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aberrations may cooperatively activate the Wnt signaling pathway (31) during the 
development of early-onset endometrioid endometrial cancer. Although an inverse 
association between immunohistochemically detected nuclear accumulation of -catenin 
and the age of endometrial cancer patients has been reported previously (32), and 
mutations of the CTNNB1 gene have been shown to be accumulated in a subset of 
endometrioid endometrial cancers arising in young and obese patients (33), the present 
study has comprehensively revealed epigenetic and genetic alterations of genes 
participating in Wnt signaling in early-onset endometrioid endometrial cancer for the first 
time. Similarly, DNA methylation alterations and gene aberrations may cooperatively 
participate in the FGF signaling pathway in late-onset endometrioid endometrial 
carcinogenesis. Although activating mutation of the FGFR2 gene has been considered a 
therapeutic target for endometrioid endometrial cancer (34, 35), its correlation with late-
onset carcinogenesis has never been reported previously. Thus, the pathways contributing 
to the development of early- and late-onset endometrial cancer appear to partially differ. 
With regard to the genome-wide DNA methylation profile, all 1,034 probes 
showing significant differences in DNA methylation levels between EE and LE samples 
again showed significant differences between LE and normal control endometrial tissue 
samples. On the other hand, only 102 probes of the 1,034 probes showed significant 
differences in DNA methylation levels between EE and normal control endometrial tissue 
samples, indicating that DNA methylation alterations for the majority of the 1,034 probes 
occurred specifically in LE samples. GO enrichment analysis indicated that 371 genes, 
for which the 1,034 probes were designed, were clearly overrepresented by 
“transcriptional factors” and were accumulated in signaling pathways participating in 
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transcriptional regulation. The late-onset-specific DNA methylation profile may modify 
the clinicopathological features of LE samples as a result of the differences in the gene 
expression profiles. In fact, myometrial invasion, one of the most important prognostic 
factors of endometrioid endometrial cancer (2), was more frequent in LE than in EE 
samples. 
Epigenetic clustering based on DNA methylation profiles showed that 
endometrioid endometrial cancers belonging to Cluster A were clinicopathologically 
more aggressive than th se belonging to Cluster B. This tendency was also evident in 
patients belonging to Cluster EA, and all patients in Cluster EA were included in Cluster 
A without exception. The 101 hallmark genes for Cluster EA may drive the development 
and progression of different tumor subtypes. For example, the DNA methylation levels 
of 18 genes, including HOXA9, HOXD10 and SOX11, were significantly correlated with 
more frequent lymphovascular tumor invasion. DNA hypermethylation of the HOXA9 
homeobox gene is reportedly associated with a higher grade of serous ovarian cancer (36), 
recurrence of bladder cancer (37) and non-small cell lung cancer (38) and mortality in 
non-infant patients with neuroblastoma (39). Decreased expression of the HOXD10 
homeobox gene has been reported in prostate (40), breast (41), thyroid (42), colorectal 
(43), ovarian (44) and endometrial (45) cancer. Promoter methylation of the SOX11 gene 
has reportedly been associated with cell growth, invasion or poor prognosis of gastric 
cancer (46), hematopoietic malignancies (47) and nasopharyngeal carcinoma (48). It is 
feasible that DNA methylation alterations of these genes participate in determining the 
clinicopathological characteristics of Cluster EA. These data indicate that 
clinicopathological features are strongly defined on the basis of DNA methylation 
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profiles, even in early-onset endometrioid endometrial cancer.
ROC analysis identified markers at CpG sites that were able to distinguish 
epigenetic Cluster EB from Cluster EA: 11 CpG sites showed AUC values of 1 for such 
discrimination, and Cluster EB of this cohort was diagnosed using the 11 marker CpG 
sites with both a sensitivity and specificity of 100%. Although some of the 11 marker 
CpGs were located in CpG islands around the TSSs, an inverse correlation between levels 
of DNA methylation and mRNA expression was not confirmed in the data for endometrial 
cancer deposited in the TCGA database (https://tcga-
data.nci.nih.gov/docs/publications/ucec_2013/) (23). Therefore, DNA methylation 
alterations of such genes may not result in alterations of expression, and such genes may 
not be potential therapeutic targets. Instead, since the present data have indicated that the 
clinicopathological features of endometrial cancers may be determined by their DNA 
methylation profiles, these 11 markers may be able to reproducibly identify less 
aggressive cancers, such as those belonging to Cluster EB. Although a validation study 
will, of course, be needed, DNA methylation diagnostics of biopsy specimens using 
appropriate marker CpG sites, such as these 11 CpG sites, may help to indicate the 
feasibility of fertility preservation therapy for patients with early-onset endometrioid 
endometrial cancer. 
Since all samples belonging to Clusters EA and EB were included in Clusters A 
and B, respectively, it is not surprising that the 11 CpG sites showed excellent AUCs even 
in ROC analysis for discrimination of the more aggressive Cluster A from the less 
aggressive Cluster B (Supplementary Table 12, available at Carcinogenesis Online): The 
11 CpG sites may also become good markers for prognostication of all age groups of 
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patients with endometrioid endometrial cancers. Moreover, the DNA methylation levels 
of the 11 CpG sites were not significantly correlated with clinicopathological parameters 
reflecting tumor aggressiveness, i.e. histological grade and stage, or patient outcome, in 
cancers of the lung, stomach, breast, colon and ovary deposited in the TCGA database 
(data not shown), suggesting that the prognostic potential of the 11 CpG sites may be 
specific to endometrioid endometrial cancers.
In summary, genome-wide DNA methylation analysis using EPIC array and 
targeted sequencing of tumor-related genes for 112 endometrial tissue samples have 
indicated that genetically and epigenetically different pathways may participate in the 
development of early- and late-onset endometrial cancers. Since DNA methylation 
profiles may determine the clinicopathological features of endometrial cancers, such 
profiling may predict tumors that are less aggressive and amenable to fertility 
preservation treatment.
Supplementary Material
Supplementary data are available at Carcinogenesis online.
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Figure legends
Figure 1. DNA methylation profiles of normal control endometrial tissue (n=31) and 
endometrial cancer tissue (n=81). (A) Principal component analysis was performed using 
the 58,958 probes showing significant differences in DNA methylation levels between 
normal control endometrial tissue and endometrial cancer tissue samples (Welch’s t test, 
adjusted Bonferroni correction [α=1.18×10-8] and endometrial cancer tissue – normal control endometrial 
tissue value of more than 0.25 or less than -0.25). (B) Manhattan plot constructed using all 
846,413 probes. The Bonferroni corrected P value (1.18×10-8) is indicated by the red line. 
The leading 10 genes, i.e. TRIM15, HIST2H3PS2, NBPF19, L1TD1, HIST2H2BA, 
NKAPL, DLX2-AS1, GRM1, ADAM12 and CFAP46, showing significant differences in 
DNA methylation levels between normal control endometrial tissue and endometrial 
cancer tissue samples (Δβendometrial cancer tissue–normal control endometrial tissue value of more than 
0.25 or less than -0.25) are labeled. N/A, not annotated (designed for the intergenic 
regions).
Figure 2. The incidence of somatic mutations (A) and copy number alterations (gain and 
loss) (B) of the 50 examined tumor-related genes in endometrial cancer tissue in the 
present cohort (n=81) and data deposited in The Cancer Genome Atlas (TCGA) database 
(https://tcga-data.nci.nih.gov/docs/publications/ucec_2013/) (n=248) (23). Genes 
showing significantly higher or lower incidence (P<0.05) in the present cohort than in the 
TCGA database are indicated by * and †, respectively.
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Figure 3. Differences in genetic and epigenetic states between early-onset endometrioid 
endometrial cancer tissue (EE) (patient age <40 yr) and late-onset endometrioid 
endometrial cancer tissue (LE). (A) The incidence of somatic mutations of the 50 
examined tumor-related genes in 34 samples of EE and 40 samples of LE. Genes showing 
a significantly higher incidence (P<0.05) of somatic mutations in EE samples than in LE 
samples and genes showing a significantly higher incidence of somatic mutations in LE 
samples than in EE samples are indicated by * and †, respectively. (B) The pathway 
“Development WNT signaling pathway” (P=3.45×10
-8
) illustrated schematically using 
MetaCore software. Genes showing DNA hypermethylation in 19 EE samples with 
somatic mutations of the CTNNB1 gene (CTNNB1-M) relative to 15 EE samples without 
such mutations (CTNNB1-W) (Welch’s t test P<0.01 and ΔβCTNNB1-M-CTNNB1-W value of 
more than 0.15) are indicated by red circles. Genes showing DNA hypomethylation in 
CTNNB1-M samples relative to CTNNB1-W samples (Welch’s t test P<0.01 and 
ΔβCTNNB1-M-CTNNB1-W value of less than -0.15) are indicated by dotted red circles. The 
CTNNB1 gene is indicated by a blue circle.
Figure 4. Epigenetic clustering of endometrioid endometrial cancer. (A) Unsupervised 
hierarchical clustering of endometrioid endometrial cancer tissue samples using DNA 
methylation levels on 63,033 probes showing significant differences in DNA methylation 
levels between 31 samples of normal control endometrial tissue and 74 samples of 
endometrioid endometrial cancer tissue (Welch’s t test, adjusted Bonferroni correction 
[α=1.18 × 10-8] and Δβendometrioid endometrial cancer tissue-normal control endometrial tissue value of more 
than 0.25 or less than -0.25). Based on DNA methylation status, 74 patients were 
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subclustered into Cluster A (n=58) and Cluster B (n=16). Correlations between this 
epigenetic clustering and clinicopathological parameters are summarized in 
Supplementary Table 8A, available at Carcinogenesis Online. (B) Unsupervised 
hierarchical clustering of early-onset endometrioid endometrial cancer tissue (EE) 
samples using DNA methylation levels on the 40,589 probes showing significant 
differences in DNA methylation between 31 normal control endometrial tissue samples 
and 34 EE samples (Welch’s t test, adjusted Bonferroni correction [α=1.18 × 10-8] and 
ΔβEE-normal control endometrial tissue value of more than 0.25 or less than -0.25). Based on DNA 
methylation status, the 34 EE patients were subclustered into Cluster EA (n=22) and 
Cluster EB (n=12). Correlations between this epigenetic clustering and 
clinicopathological parameters of the patients are summarized in Supplementary Table 
8B, available at Carcinogenesis Online. Probe Clusters I to V are shown on the left side 
of the heatmap. (C) Venn diagram showing the relationship between Clusters A and B of 
endometrioid endometrial cancer tissue samples and Clusters EA and EB of EE samples. 
All samples belonging to Cluster EA are included in Cluster A, whereas all samples 
belonging to Cluster EB are included in Cluster B without exception.
Figure 5. Scattergrams of DNA methylation levels for all 11 probes showing an area 
under the curve value of 1 in receiver operating characteristic curve analysis for 
discrimination of EB samples (n=12) from EA samples (n=22). P values by Welch’s t test 
for each probe are shown in each panel. Cutoff values (CVs) are shown by a dotted line 
in each panel. Using each probe and its CV, EB samples were discriminated from EA 
samples with 100% sensitivity and specificity.
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Table 1. Top 20 statistically significant GO molecular functions revealed by MetaCore software analysis using the 371 genes, for 
which the 1,034 probes showing differences in DNA methylation levels between samples of early-onset endometrioid endometrial 
cancer tissue (patient age <40 years) and late-onset endometrioid endometrial cancer tissue were designed (listed in Supplementary 
Table 4, available at Carcinogenesis Online).
Molecular functions P value Included genes showing differences in DNA methylation levels
Sequence-specific DNA binding* 2.05 × 10-19
ASCL1, ASCL2, ASCL4, BARHL2, DMARTA2, DRGX, EN1, EVX1, EVX2, FEZF2, FLI1, FOXD3, FOXE1, 
FOXI2, GATA4, GCM2, HAND2, HIC1, IRF4, LHX1, LHX4, LHX5, MNX1, MSC, MKX1-1, MYOD1, NKX2-6, 
NKX6-2, STN1, ONECUT2, OTP, OTX1, PAX3, PAX5, PAX6, PAX7, PHOX2A, PITX2, POU3F3, POU4F2, 
PRDM14, PROX1, RAX, SALL3, SATB2, SIX6, SOX1, SOX11, SOX14, SOX2,TBXT, TBX15, TBX18, TBX5, 
TLX2, TP73, VSX1, ZFHX4, ZIC5, ZNF516
Transcription factor activity, 
sequence-specific DNA binding* 2.39 × 10
-19
ASCL1, ASCL2, ASCL4, BARHL2, BHLHE22, BHLHE23, BNC1, DMRTA2, DRGX, DBX1, EN1, EVX1, EVX2, 
FEZF2, FLI1, FOXD3, FOXE1, FOXI2, SKOR1, GATA4, GCM2, GFI1, HAND2, HIC1, IRF4, LHX1, LHX4, 
LHX5, MNX1, MSC, MKX1-1, MYOD1, NKX2-6, NKX6-2, OLIG2, ONECUT1, ONECUT2, OTP, OTX1, 
PAX3, PAX5, PAX6, PAX7, PHOX2A, PITX2, POU3F3, POU4F2, POU6F2, PRDM14, PROX1, RAX, SALL3, 
SATB2, SIM1, SIX6, SOX1, SOX11, SOX14, SOX2, TBXT, TBX15, TBX18, TBX5, TLX2, TP73, VSX1, ZFHX4, 
ZIC5, ZNF132, ZNF229, ZNF334, ZNF516, ZNF667, ZSCAN1, ZSCAN23
Nucleic acid binding transcription 
factor activity* 2.48 × 10
-19
ASCL1, ASCL2, ASCL4, BARHL2, BHLHE22, BHLHE23, BNC1, DMRTA2, DRGX, DBX1, EN1, EVX1, EVX2, 
FEZF2, FLI1, FOXD3, FOXE1, FOXI2, SKOR1, GATA4, GCM2, GFI1, HAND2, HIC1, IRF4, LHX1, LHX4, 
LHX5, MNX1, MSC, MKX1-1, MYOD1, NKX2-6, NKX6-2, OLIG2, ONECUT1, ONECUT2, OTP, OTX1, 
PAX3, PAX5, PAX6, PAX7, PHOX2A, PITX2, POU3F3, POU4F2, POU6F2, PRDM14, PROX1, RAX, SALL3, 
SATB2, SIM1, SIX6, SOX1, SOX11, SOX14, SOX2, TBXT, TBX15, TBX18, TBX5, TLX2, TP73, VSX1, ZFHX4, 
ZIC5, ZNF132, ZNF229, ZNF334, ZNF516, ZNF667, ZSCAN1, ZSCAN23
RNA polymerase II transcription 
factor activity, sequence-specific 
DNA binding*
3.14 × 10-16
ASCL1, ASCL2, ASCL4, BARHL2, BHLHE22, BHLHE23, BNC1, DMRTA2, DRGX, DBX1, EN1, EVX1, EVX2, 
FEZF2, FLI1, FOXD3, FOXE1, FOXI2, SKOR1, GATA4, GCM2, GFI1, HAND2, HIC1, IRF4, LHX1, LHX4, 
LHX5, MNX1, MSC, MKX1-1, MYOD1, NKX2-6, NKX6-2, OLIG2, ONECUT1, ONECUT2, OTP, OTX1, 
PAX3, PAX5, PAX6, PAX7, PHOX2A, PITX2, POU3F3, POU4F2, POU6F2, PRDM14, PROX1, RAX, SALL3, 
SATB2, SIM1, SIX6, SOX1, SOX11, SOX14, SOX2, TBXT, TBX15, TBX18, TBX5, TLX2, TP73, VSX1, ZFHX4, 
ZIC5, ZNF132, ZNF229, ZNF334, ZNF516, ZNF667, ZSCAN1, ZSCAN23
DNA binding* 2.05 × 10-10
ASCL1, ASCL2, ASCL4, BARHL2, BHLHE22, BHLHE23, BNC1, DMRTA2, DRGX, DBX1, EN1, EVX1, EVX2, 
FEZF2, FLI1, FOXD3, FOXE1, FOXI2, SKOR1, GATA4, GCM2, GFI1, HAND2, HIC1, IRF4, LHX1, LHX4, 
LHX5, MNX1, MSC, MKX1-1, MYOD1, NKX2-6, NKX6-2, OLIG2, ONECUT1, ONECUT2, OTP, OTX1, 
PAX3, PAX5, PAX6, PAX7, PHOX2A, PITX2, POU3F3, POU4F2, POU6F2, PRDM14, PROX1, RAX, SALL3, 
SATB2, SIM1, SIX6, SOX1, SOX11, SOX14, SOX2, TBXT, TBX15, TBX18, TBX5, TLX2, TP73, VSX1, ZFHX4, 
ZIC5, ZNF132, ZNF229, ZNF334, ZNF516, ZNF667, ZSCAN1, ZSCAN23
Transcription regulatory region 
sequence-specific DNA binding* 2.15 × 10
-10
ASCL1, ASCL2, ASCL4, BARHL2, BHLHE22, EN1, FEZF2, FLI1, FOXD3, GATA4, HAND2, IRF4, MNX1, 
MSC, MKX1-1, MYOD1, NKX6-2, ONECUT2, OTX1, PAX5, PAX6, PHOX2A, PITX2, POU4F2, PRDM14, 
PROX1, RAX, SATB2, SOX1, SOX11, SOX2, TBXT, TBX15, TBX18, TBX5, ZIC5, ZNF516
Transcription factor activity, RNA 
polymerase II core promoter proximal 
region sequence-specific binding*
2.81 × 10-10
ASCL1, ASCL2, BARHL2, EN1, FLI1, GCM2, GIF1, HAND2, IRF4, MYOD1, NKX6-2, ONECUT1, 
ONECUT2, OTX1, PAX5, PAX6, PHOX2A, PITX2, POU4F2, PROX1, RAX, SATB2, SOX1, SOX11, SOX2, 
TBX15, TBX18, TP73
Neurokinin receptor binding 5.08 × 10-10 TAC1
Substance P receptor binding 5.08 × 10-10 TAC1
Sequence-specific double-stranded 
DNA binding* 7.65 × 10
-10
ASCL1, ASCL2, ASCL4, BARHL2, EN1, FEZF2, FLI1, FOXD3, GATA4, HAND2, IRF4, LHX1, MSC, MKX1-
1, MYOD1, NKX6-2, ONECUT2, OTX1, PAX5, PAX6, PHOX2A, PITX2, POU4F2, PRDM14, PROX1, RAX, 
SATB2, SOX1, SOX11, SOX2, TBXT, TBX15, TBX18, TBX5, TP73, ZIC5, ZNF516
Transcription regulatory region DNA 
binding* 9.47 × 10
-10
ASCL1, ASCL2, ASCL4, BARHL2, BHLHE22, EN1, FEZF2, FLI1, FOXD3, GATA4, GFI1, HAND2, IRF4, 
LHX1, MSC, MKX1-1, MYOD1, NKX6-2, ONECUT2, OTX1, PAX5, PAX6, PHOX2A, PITX2, POU4F2, 
PRDM14, PROX1, RAX, SATB2, SOX1, SOX11, SOX2, TBXT, TBX15, TBX18, TBX5, TP73, ZIC5, ZNF516
Regulatory region DNA binding* 1.01 × 10-9
ASCL1, ASCL2, ASCL4, BARHL2, BHLHE22, EN1, FEZF2, FLI1, FOXD3, GATA4, GFI1, HAND2, IRF4, 
LHX1, MSC, MKX1-1, MYOD1, NKX6-2, ONECUT2, OTX1, PAX5, PAX6, PHOX2A, PITX2, POU4F2, 
PRDM14, PROX1, RAX, SATB2, SOX1, SOX11, SOX2, TBXT, TBX15, TBX18, TBX5, TP73, ZIC5, ZNF516
Regulatory region nucleic acid 
binding* 1.13 × 10
-9
ASCL1, ASCL2, ASCL4, BARHL2, BHLHE22, EN1, FEZF2, FLI1, FOXD3, GATA4, GFI1, HAND2, IRF4, 
LHX1, MSC, MKX1-1, MYOD1, NKX6-2, ONECUT2, OTX1, PAX5, PAX6, PHOX2A, PITX2, POU4F2, 
PRDM14, PROX1, RAX, SATB2, SOX1, SOX11, SOX2, TBXT, TBX15, TBX18, TBX5, TP73, ZIC5, ZNF516
Neuropeptide receptor activity 3.30 × 10-9 GALR1, QRFPR, GPR139, NPFFR2, NPY2R, NPY5R, PROKR2, SSTR1, SSTR4, SORCS3
Gated channel activity 6.48 × 10-9 CACNG7, CNGA3, GABRA1, GABRA2, GABRB1, GLRA3, GRIA4, KCNAB1, KCNH8, KCNK9, KCNQ5, KCNA6, KCNJ3, KCNA1, KCNA3, KCNA4, KCNV1, GRIN3A, CACNA1A, RYR2, KCNT2, TTYH1, CHRNA4
Double-stranded DNA binding* 7.49 × 10-9
ASCL1, ASCL2, ASCL4, BARHL2, EN1, FEZF2, FLI1, FOXD3, FOXE1, GATA4, HAND2, IRF4, LHX1, MSC, 
MKX1-1, MYOD1, NKX6-2, ONECUT2, OTX1, PAX5, PAX6, PHOX2A, PITX2, POU4F2, PRDM14, PROX1, 
RAX, SATB2, SOX1, SOX11, SOX2, TBXT, TBX15, TBX18, TBX5, TP73, ZIC5, ZNF516
RNA polymerase II regulatory region 
sequence-specific DNA binding* 9.49 × 10
-9
ASCL1, ASCL2, ASCL4, BARHL2, EN1, FEZF2, FLI1, FOXD3, GATA4, HAND2, IRF4, MSC, MYOD1, 
NKX6-2, ONECUT2, OTX1, PAX5, PAX6, PHOX2A, PITX2, POU4F2, PRDM14, PROX1, RAX, SATB2, 
SOX1, SOX11, TBXT, TBX15, TBX18, TBX5, TP73, ZIC5
Voltage-gated potassium channel 
activity 1.06 × 10
-8
CNGA3, KCNAB1, KCNH8, KCNK9, KCNQ5, KCNA6, KCNJ3, KCNA1, KCNA3, KCNA4, KCNV1, KCNT2
RNA polymerase II regulatory region 
DNA binding* 1.19 × 10
-8
ASCL1, ASCL2, ASCL4, BARHL2, EN1, FEZF2, FLI1, FOXD3, GATA4, HAND2, IRF4, MSC, MYOD1, 
NKX6-2, ONECUT2, OTX1, PAX5, PAX6, PHOX2A, PITX2, POU4F2, PRDM14, PROX1, RAX, SATB2, 
SOX1, SOX11, TBXT, TBX15, TBX18, TBX5, TP73, ZIC5
Transcriptional activator activity, 
RNA polymerase II transcription 
regulatory region sequence-specific 
binding*
1.24 × 10-8
BARHL2, FEZF2, FLI1, GATA4, GCM2, HAND2, IRF4, LHX4, MYOD1, ONECUT1, ONECUT2, OTX1, 
PAX5, PAX6, PHOX2A, PITX2, POU4F2, RAX, SATB2, SIX6, SOX1, SOX11, SOX2, TBX5, TLX2,, TP73
*GO molecular functions involved in DNA binding or transcriptional regulation. Genes for which the protein class is a transcription 
factor are indicated by underlining.
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